NBTX Overview

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is3.50 USD with a low forecast of 3.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nanobiotix SA revenue for the last quarter amounts to NaN USD, decreased

Nanobiotix SA. EPS for the last quarter amounts to USD, decreased

Nanobiotix SA (NBTX) has 108 emplpoyees as of March 25 2026.

Today NBTX has the market capitalization of 1.42B USD.